The endocrine background of human renal cell carcinoma. II. Attempt to induce the R-5020-binding components by oestrogens.
In an attempt to elevate the concentration of progestin-binding components in human renal cell carcinoma, 24 patients were treated prior to tumour nephrectomy with various doses of oestrogens, potent inducers of progestin receptor synthesis. Low-dose oestrogen treatment was found to be insufficient to significantly induce progestin-binder synthesis in the tumour tissue. In the carcinoma of patients receiving high-dose oestrogen treatment, the average concentration of R-5020-binding sites did not differ from that of the low-dose group. However, 2 out of these patients (12.5%) exhibited R-5020-binder concentrations in the tumour tissue which exceeded the highest quantities of progestin-binding components found in 88 untreated controls previously analysed in our laboratory.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism*; D000368:Aged; D003600:Cytosol / Q000378:metabolism; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000378:metabolism; D009649:Norpregnadienes / Q000378:metabolism*; D011397:Promegestone / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000096:biosynthesis* / Q000187:drug effects; D011980:Receptors, Progesterone / Q000096:biosynthesis
D004967:Estrogens; D009649:Norpregnadienes; D011956:Receptors, Cell Surface; D011980:Receptors, Progesterone; D011397:Promegestone